RU2015151216A - Собетиром для лечения заболеваний, связанных с миелинизацией - Google Patents

Собетиром для лечения заболеваний, связанных с миелинизацией Download PDF

Info

Publication number
RU2015151216A
RU2015151216A RU2015151216A RU2015151216A RU2015151216A RU 2015151216 A RU2015151216 A RU 2015151216A RU 2015151216 A RU2015151216 A RU 2015151216A RU 2015151216 A RU2015151216 A RU 2015151216A RU 2015151216 A RU2015151216 A RU 2015151216A
Authority
RU
Russia
Prior art keywords
disease
pharmaceutically acceptable
acceptable salt
sobetir
condition
Prior art date
Application number
RU2015151216A
Other languages
English (en)
Russian (ru)
Inventor
Томас С. СКАНЛАН
Мередит ХАРТЛИ
Эндрю ПЛАЧЕК
Марко РИГИ
Деннис БУРДЕТТ
Гейл МАРРАЧЧИ
Прия ЧАУДХАРИ
Original Assignee
Орегон Хелс Энд Сайенс Юниверсити
Зэ Юнайтид Стейтс Гавермент Эз Репризентид Бай Зэ Департмент Оф Ветеранс Афэрс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Орегон Хелс Энд Сайенс Юниверсити, Зэ Юнайтид Стейтс Гавермент Эз Репризентид Бай Зэ Департмент Оф Ветеранс Афэрс filed Critical Орегон Хелс Энд Сайенс Юниверсити
Publication of RU2015151216A publication Critical patent/RU2015151216A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
RU2015151216A 2013-05-03 2014-02-05 Собетиром для лечения заболеваний, связанных с миелинизацией RU2015151216A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361819467P 2013-05-03 2013-05-03
US61/819,467 2013-05-03
PCT/US2013/053640 WO2014178892A1 (en) 2013-05-03 2013-08-05 Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
USPCT/US2013/0053640 2013-08-05
PCT/US2014/014943 WO2014178931A1 (en) 2013-05-03 2014-02-05 Sobetirome in the treatment of myelination diseases

Publications (1)

Publication Number Publication Date
RU2015151216A true RU2015151216A (ru) 2017-06-08

Family

ID=51843844

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015151216A RU2015151216A (ru) 2013-05-03 2014-02-05 Собетиром для лечения заболеваний, связанных с миелинизацией

Country Status (12)

Country Link
US (3) US10226438B2 (cg-RX-API-DMAC7.html)
EP (1) EP2991670B8 (cg-RX-API-DMAC7.html)
JP (4) JP2016517883A (cg-RX-API-DMAC7.html)
CN (1) CN105431163A (cg-RX-API-DMAC7.html)
AU (1) AU2014260468A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015027682A2 (cg-RX-API-DMAC7.html)
CA (1) CA2911309A1 (cg-RX-API-DMAC7.html)
ES (1) ES2745532T3 (cg-RX-API-DMAC7.html)
MX (2) MX379043B (cg-RX-API-DMAC7.html)
RU (1) RU2015151216A (cg-RX-API-DMAC7.html)
SG (2) SG10201709090UA (cg-RX-API-DMAC7.html)
WO (2) WO2014178892A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014178892A1 (en) * 2013-05-03 2014-11-06 Scanlan Thomas S Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
AU2015253100B2 (en) 2014-04-30 2018-01-18 The Johns Hopkins University Dendrimer compositions and their use in treatment of diseases of the eye
CN115350285A (zh) 2014-08-13 2022-11-18 约翰霍普金斯大学 树枝状聚合物到脑肿瘤的选择性传递
US20170119899A1 (en) * 2015-10-29 2017-05-04 The Johns Hopkins University Compositions and methods for treatment of peroxisomal disorders and leukodystrophies
EP3445372A4 (en) * 2016-04-22 2020-03-25 Viking Therapeutics, Inc. USE OF THYROID BETA AGONISTS
EP3445373B1 (en) 2016-04-22 2024-08-21 Viking Therapeutics, Inc. Use of thyroid beta-agonists
LT3457851T (lt) 2016-05-18 2021-10-11 Oregon Health & Science University Sobetiromo dariniai
AU2017310535B2 (en) * 2016-08-12 2021-11-11 Oregon Health & Science University Amide compounds, pharmaceutical compositions thereof, and methods of using the same
WO2018183940A1 (en) * 2017-03-31 2018-10-04 Neurovia, Inc. Methods and compositions for treating niemann-pick disease
IL270169B2 (en) 2017-04-27 2024-08-01 Univ Johns Hopkins Dendrimer preparations for use in angiography
WO2018208707A1 (en) * 2017-05-08 2018-11-15 Neurovia, Inc. Methods and compositions for treating demyelinating diseases
US10780069B2 (en) * 2017-05-18 2020-09-22 University of Pittsburgh—of the Commonwealth System of Higher Education Use of GC-1 in transplant related population
US11660281B2 (en) 2017-06-29 2023-05-30 Yale University Compositions and methods of treating or preventing fibrotic lung diseases
US11633433B2 (en) * 2017-07-18 2023-04-25 Keio University Anti-bacterial composition against TH1 cell-inducing bacteria
CN111615528A (zh) 2017-11-10 2020-09-01 约翰霍普金斯大学 树枝状聚合物递送系统和其使用方法
CN113423684A (zh) 2018-12-12 2021-09-21 速通医疗公司 新型拟甲状腺素药
US11667606B2 (en) 2019-03-01 2023-06-06 Autobahn Therapeutics, Inc. Thyromimetics
MX2022006470A (es) 2019-11-29 2022-08-04 Autobahn Therapeutics Inc Tiromimeticos novedosos.
WO2021113662A2 (en) 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery to the eye
CN111116684B (zh) * 2019-12-31 2020-09-25 厦门甘宝利生物医药有限公司 一种具有甲状腺激素受体激动剂特性的肝靶向化合物及其药物组合物
CN115569233B (zh) * 2022-10-17 2023-07-14 湖南大学 既能吸光又能与自由基反应的高效光抑制剂的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
WO1997021993A2 (en) 1995-12-13 1997-06-19 The Regents Of The University Of California Nuclear receptor ligands and ligand binding domains
EP1003530A4 (en) 1996-08-20 2001-10-04 Univ California EYE TREATMENT USING SYNTHETIC THYROID HORMONE COMPOSITIONS
US5883294A (en) 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs
KR20010053277A (ko) 1998-06-30 2001-06-25 린다 에스. 스티븐슨 갑상선 호르몬 유사체 및 그 제조 방법
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US7302347B2 (en) 2002-12-10 2007-11-27 The Regents Of The University Of California Method for creating specific, high affinity nuclear receptor pharmaceuticals
US8071134B2 (en) * 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
CN1878545A (zh) * 2003-09-15 2006-12-13 奥德威研究院 甲状腺激素类似物及其使用方法
WO2006012015A2 (en) 2004-06-29 2006-02-02 Oregon Health And Science University Methods and compositions for nerve regeneration
AU2005284879B2 (en) 2004-09-15 2011-04-14 Albany College Of Pharmacy And Health Sciences Thyroid hormone analogs for promoting angiogenesis
WO2006105205A1 (en) 2005-03-29 2006-10-05 University Of Kentucky Research Foundation Sublingual spray for the treatment of pain
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
KR20090071652A (ko) * 2006-10-20 2009-07-01 바이오겐 아이덱 엠에이 인코포레이티드 가용성 림프독소-베타-수용체를 이용한 탈수초성 장애의 치료
US8623861B2 (en) 2006-11-03 2014-01-07 Xin-Min Li Method of treating demyelination diseases
FI20075245A0 (fi) * 2007-04-11 2007-04-11 Markku Ahotupa Menetelmä oksidatiivisen metabolian arvioimiseksi
PL2187882T3 (pl) * 2007-07-11 2013-05-31 Medicinova Inc Leczenie postępującej choroby neurodegeneracyjnej ibudilastem
EP2242745A1 (de) * 2008-02-07 2010-10-27 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
KR20160029870A (ko) * 2008-04-21 2016-03-15 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
EP2437730A4 (en) 2009-05-20 2014-02-26 Lingual Consegna Pty Ltd ORAL AND / OR SUBLINGUAL THERAPEUTIC FORMULATION
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
AU2011343429B2 (en) 2010-12-16 2016-10-20 Sunovion Pharmaceuticals Inc. Sublingual films
JP6060268B2 (ja) * 2012-10-25 2017-01-11 ボルボ トラック コーポレイション 車両用電子制御エアブレーキシステム、そのようなシステムを備える車両及びそのようなシステムを制御する方法
WO2014178892A1 (en) * 2013-05-03 2014-11-06 Scanlan Thomas S Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy

Also Published As

Publication number Publication date
WO2014178892A8 (en) 2015-12-17
EP2991670A1 (en) 2016-03-09
SG10201709090UA (en) 2017-12-28
MX379043B (es) 2025-03-10
JP6360552B2 (ja) 2018-07-18
WO2014178892A1 (en) 2014-11-06
WO2014178931A1 (en) 2014-11-06
US10226438B2 (en) 2019-03-12
JP6360552B6 (ja) 2018-08-15
US11510887B2 (en) 2022-11-29
WO2014178931A8 (en) 2015-11-26
EP2991670B1 (en) 2019-07-03
CA2911309A1 (en) 2014-11-06
US20200405669A1 (en) 2020-12-31
JP2018162321A (ja) 2018-10-18
MX2015015228A (es) 2016-10-03
AU2014260468A1 (en) 2015-11-19
US20190175531A1 (en) 2019-06-13
BR112015027682A2 (pt) 2017-08-29
US20160081955A1 (en) 2016-03-24
HK1222552A1 (en) 2017-07-07
EP2991670A4 (en) 2017-01-18
JP2016517883A (ja) 2016-06-20
JP2018141024A (ja) 2018-09-13
CN105431163A (zh) 2016-03-23
EP2991670B8 (en) 2019-09-11
JP2016517884A (ja) 2016-06-20
ES2745532T3 (es) 2020-03-02
SG11201509012QA (en) 2015-11-27
MX2021000538A (es) 2021-04-28

Similar Documents

Publication Publication Date Title
RU2015151216A (ru) Собетиром для лечения заболеваний, связанных с миелинизацией
JP2016517884A5 (cg-RX-API-DMAC7.html)
Hayley et al. Neuroplasticity and the next wave of antidepressant strategies
Barnes et al. Intravenous methylprednisolone for multiple sclerosis in relapse.
SI2625199T1 (en) Procedures for treating psoriasis using IL-17 antagonists
FI3478712T3 (fi) Anti-N3pGlu beeta-amyloidipeptidi -vasta-aineita ja niiden käyttöjä
JP2016501865A5 (cg-RX-API-DMAC7.html)
CA2602950A1 (en) Methods for the treatment of central nervous system injury via a tapered administration of progesterone
Yap et al. Profiling neuroprotective potential of trehalose in animal models of neurodegenerative diseases: a systematic review
Writing Group on Behalf of the Edaravone (MCI-186) ALS 19 Study Group Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis
Oh et al. Effect of ketamine and midazolam on oculocardiac reflex in pediatric strabismus surgery
JP2016510343A5 (cg-RX-API-DMAC7.html)
Kondo et al. Comparison of two low dose ACTH therapies for West syndrome: their efficacy and side effect
Kim et al. Chronic inflammatory demyelinating polyneuropathy: plasmapheresis or cyclosporine can be good treatment options in refractory cases
JP2015508824A5 (cg-RX-API-DMAC7.html)
JP2020531527A5 (cg-RX-API-DMAC7.html)
JP2016528171A5 (cg-RX-API-DMAC7.html)
FI3590960T3 (fi) Perifeeristen hermojen IgG-stimuloitu remyelinaatio
Li et al. Telitacicept for minimal change disease
CN101829117A (zh) 吴茱萸碱在制备治疗阿尔茨海默病的药物中的应用
Smith Anesthestic agents and status epilepticus
Polverino et al. Case report: atypical Parkinsonism following SARS-CoV-2 infection
JP2018500375A5 (cg-RX-API-DMAC7.html)
Tian et al. Evaluation of N2O inhalation and oral midazolam conscious sedation in pediatric dentistry of children with intellectual disability
Li et al. The involvement of the dysfunctional insulin receptor signaling system in long COVID patients with diabetes and chronic pain and its implications for the clinical management using taVNS

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20181126